{"filings":[{"id":472076,"accession_number":"0001493152-26-023889","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-05-15T20:45:37+00:00","items":["3.01","9.01"],"status":"ready","headline":"Glucotrack receives second Nasdaq delisting notice; plans to appeal by May 18","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First notice on May 11: non-compliance with minimum bid price of $1.00.","Second notice on May 15: stockholders' equity below $2.5M; additional delisting basis.","Company intends to request hearing by May 18 to appeal both deficiencies.","No assurance of success; stock (GCTK) faces potential delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":445196,"accession_number":"0001493152-26-023202","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-05-14T21:27:11+00:00","items":["2.02","9.01"],"status":"ready","headline":"Glucotrack Q1 net loss $4.3M, IDE submitted to FDA for implantable CGM","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.3M vs $6.8M YoY; cash $3.9M as of March 31, 2026.","Submitted Investigational Device Exemption (IDE) to FDA for fully implantable CBGM; targeting U.S. clinical trial launch in 2H 2026.","Reduced promissory note from $3.6M to ~$1.6M via stock exchange; drew $1.0M under equity line post-quarter.","R&D expenses $2.1M, G&A $2.1M; cash runway expected into early 3Q 2026.","Peer-reviewed data in IEEE Sensors and J. Diabetes Research show sensor stability and 6.8% MARD over 240 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93279,"accession_number":"0001493152-26-021706","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack submits IDE to FDA for US clinical study of implantable CBGM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Glucotrack submitted an IDE application to the FDA to initiate a US clinical study of its fully implantable continuous blood glucose monitoring (CBGM) system.","CBGM is designed for 3-year sensor longevity, blood-based accuracy, and no on-body wearable component.","Company plans to proceed with US clinical study following FDA review and approval of the IDE.","IDE submission follows years of preclinical evaluation and iterative engineering; data support advancing to clinical evaluation.","CEO Paul Goode stated the submission reflects progress toward offering a discreet, accurate CGM option for diabetes patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93278,"accession_number":"0001493152-26-020747","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Glucotrack converts $988k note into 1.3M shares, reduces debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged a $988k partitioned promissory note for 1,300,000 common shares with an existing investor.","No cash or other consideration paid by the investor; debt reduction with no immediate cash outlay.","Beneficial ownership limitation at 19.9% may cause the exchange to occur in tranches.","Shares issued under Section 3(a)(9) exemption as exchange for outstanding securities.","Company also released an updated investor presentation furnished as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93277,"accession_number":"0001493152-26-019788","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack publishes peer-reviewed study showing CBGM accuracy MARD 6.8% over 240 days in ovine model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study in Journal of Diabetes Research shows weighted average MARD of 6.8% across 79 IV glucose tolerance tests in ovine model.","34 devices implanted in 17 sheep; no device-related adverse events observed over up to 240 days.","Results support path to IDE submission with FDA for further clinical development toward commercialization.","Prior first-in-human study demonstrated MARD of 7.7% with 99% data capture and no serious adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93276,"accession_number":"0001493152-26-016507","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Glucotrack exchanges $600K promissory note for 895,000 common shares in debt-to-equity swap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partitioned $600K from $3.6M original note and exchanged it for 895K shares of common stock.","Exchange done under Section 3(a)(9) exemption; no cash or other consideration paid by investor.","Issuance subject to 19.9% beneficial ownership limitation; shares may be issued in tranches.","Original note reduced by $600K, otherwise remains in full force.","Holding period of original note (Sept 2025) tacks to exchange shares for Rule 144 purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104764,"accession_number":"0001493152-26-013654","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Glucotrack reports FY2025 net loss $19.4M; cash $7.4M; plans IDE filing Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2025 was $19.4M, down from $22.6M in 2024; no product revenue.","Cash and equivalents $7.4M at Dec 31, 2025, up from $5.6M; raised $4.0M private placement in Dec 2025.","R&D expenses $9.8M vs $9.5M; G&A $6.3M vs $5.1M year-over-year.","Expects to file IDE with FDA in Q2 2026 to start US clinical feasibility study of implantable CBGM in H2 2026.","Believes existing cash sufficient only through Spring 2026 to fund IDE submission and trial initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104763,"accession_number":"0001493152-26-013095","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack to file IDE with FDA for implantable CBGM in Q2 2026, citing positive trial results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brazil first-in-human study (Dec 2024-Jan 2025) showed MARD 7.7%, 99% data capture, and zero serious adverse events.","Australia feasibility study started July 2025; findings are incorporated for planned US trial.","Three US patents issued Oct/Nov 2025 covering sensor chemistry, intravascular lead, and low-power electronics.","Expects to file IDE with FDA in Q2 2026 and initiate US clinical study in H2 2026, pending approval.","Reinforced commercial foundation: market research, reimbursement pathway, dual-source manufacturing, seasoned leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104762,"accession_number":"0001493152-26-010049","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Glucotrack shareholders approve stock issuances for ELOC and warrants; ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Votes: ELOC proposal: 126,610 for, 18,261 against, 7,846 abstain, 293,631 non-votes.","Warrant issuance proposal: 26,134 for, 18,151 against, 7,841 abstain, 293,631 non-votes, 100,591 excluded shares.","Auditor ratification passed overwhelmingly: 431,871 for, 4,108 against, 10,369 abstain.","Quorum was 44.1% (446,348 of 1,011,279 shares outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104761,"accession_number":"0001493152-26-004158","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack receives USPTO approval for three CBGM patents","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three US patents issued by USPTO: US 12,453,494 (Oct 28, 2025), US 12,458,257 and US 12,458,258 (Nov 4, 2025).","Patents protect proprietary sensor chemistry, intravascular lead design, and low-power electronics for the CBGM platform.","The patents strengthen Glucotrack's competitive position and IP protection as it advances its implantable CBGM toward commercialization.","Glucotrack's CBGM is a long-term implantable device with up to 3-year sensor longevity, no wearable component, and direct blood glucose measurement.","The system measures glucose from blood, aiming to provide real-time readings with less lag than interstitial fluid sensors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121042,"accession_number":"0001493152-25-029791","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Glucotrack raises $4.0M via private placement of pre-funded and common warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.0M from sale of 1,033,591 pre-funded warrants and 2,067,182 common warrants at $3.87/unit.","Common warrants exercise price $3.87, not exercisable until stockholder approval, expire 5 years after approval.","Net proceeds for working capital and general corporate purposes.","Officers and directors entered 90-day lock-up agreements restricting share transfers.","Curvature Securities acted as sole placement agent; receives 7% cash fee and warrants for 124,030 shares at $4.257."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121041,"accession_number":"0001493152-25-029216","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack issues investor presentation; no material details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Issued an investor presentation on December 29, 2025.","Filing text contains no financial or operational specifics.","Presentation content was not included in the 8-K exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121040,"accession_number":"0001493152-25-022305","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Glucotrack reports Q3 net loss of $4.2M; cash $7.9M to fund through Q1 2026; IDE submission Spring 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net loss $4.2M ($4.64 per share) vs $5.1M in Q3 2024; nine-month net loss $15.8M.","Cash and equivalents $7.9M at Sep 30, 2025; expected to fund operations through first quarter 2026.","Secured $3M convertible note ($3.6M principal) and $20M ELOC; proceeds to repay note and eliminate warrant dilution.","IDE submission for CBGM to FDA expected Spring 2026; long-term feasibility study initiated in Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":30.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121039,"accession_number":"0001493152-25-021320","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":[],"status":"ready","headline":"Glucotrack special meeting adjourned and cancelled due to lack of quorum","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Only 17.6% of 158,370 outstanding shares were represented at reconvened meeting on Nov 7, 2025.","Meeting was permanently adjourned and cancelled because quorum was not achieved.","This follows an earlier adjournment on Oct 31, 2025 for the same reason.","No proposals were voted on; no business was conducted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121038,"accession_number":"0001493152-25-020992","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":[],"status":"ready","headline":"Glucotrack special meeting adjourned due to lack of quorum; reconvenes Nov 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Only 16.4% of outstanding shares (899,410 total) were represented, failing to constitute a quorum.","Adjournment proposal approved: 136,928 votes for, 8,655 against, 1,923 abstain.","Meeting adjourned to November 7, 2025 at 12:00 p.m. ET to solicit additional proxies for the Issuance Proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121037,"accession_number":"0001493152-25-020607","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack reconvenes special meeting Nov 7 for vote on $20M equity purchase with Sixth Borough Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting reconvenes November 7, 2025 at 12 p.m. ET to vote on Equity Purchase Agreement with Sixth Borough Capital Fund LP.","Agreement allows issuance of more than 20% of outstanding common stock for up to $20 million under NASDAQ Rule 5635(d).","Record date for voting is September 23, 2025; Board unanimously recommends voting FOR all proposals.","Shareholders can vote by telephone, online, or by returning proxy card; assistance available via Sodali & Co."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121036,"accession_number":"0001493152-25-020072","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack adds Dr. Usman Latif to clinical advisory team for integrated glucose monitoring","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appoints Usman Latif, MD, MBA, a neuromodulation and PDN expert, to its clinical advisory team.","Dr. Latif is Associate Professor at Kansas University Medical Center and board-certified anesthesiologist.","Company aims to integrate glucose sensing into spinal cord stimulator leads for PDN patients.","PDN affects ~1 in 5 Americans with diabetes, over 7 million people.","Long-term preclinical study completed showing feasibility and safety of epidural glucose monitoring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121035,"accession_number":"0001493152-25-019834","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack reminds shareholders to vote on Oct 31 special meeting for equity purchase with Sixth Borough Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting on October 31, 2025 at 12 p.m. ET; record date is September 23, 2025.","Proposal concerns an Equity Purchase Agreement with Sixth Borough Capital Fund.","Board unanimously recommends voting 'FOR' all proposals; proxy statement filed Oct 3.","Shareholders encouraged to vote by telephone, online, or proxy; help via Sodali & Co."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137670,"accession_number":"0001493152-25-013290","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Glucotrack issues $3.6M convertible note at $3M price; ELOC proceeds to repay","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $3.6M convertible promissory note for $3M purchase price ($600K OID), no interest, due in 12 months or upon Qualified Financing.","Conversion price floor of $4.87/share; converts into equity of next financing raising ≥$5M.","Simultaneously entered $20M ELOC with Sixth Borough Capital; 100% of ELOC net proceeds repay note pre-stockholder approval, 50% post.","Note is unsecured, no restrictive covenants; standard events of default include bankruptcy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137669,"accession_number":"0001493152-25-013094","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Glucotrack signs up to $20M equity purchase agreement with Sixth Borough Capital Fund","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor committed to buy up to $20M of common stock over 24 months at company's discretion.","Regular purchase price at 97% of VWAP; add-on/intraday at 95% of VWAP.","Commitment fee of 1.5% ($300k) payable in cash, stock, or warrants on Commencement Date.","Exchange cap of 179,792 shares (19.99% of outstanding) unless stockholder approval or price condition met.","Investor prohibited from short sales; company may terminate pact with 1 business day notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137668,"accession_number":"0001493152-25-011975","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glucotrack H1 net loss $11.6M; cash $9.6M; on track to implant first CBGM patients in Australia Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.6M for H1 2025 vs $7.4M prior year; operating expenses rose $0.9M.","Cash and equivalents $9.6M as of June 30, 2025, expected to fund operations through 2025.","Received ethical approval in Australia; first patient implants in multicenter feasibility study expected Q3 2025.","Repurchased Series A warrants, eliminating warrant liability accounting and dilution overhang.","Positive first-in-human CBGM data reported: MARD 7.7%, 99% data capture, no serious adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":34.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137667,"accession_number":"0001493152-25-011630","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack appoints David S. Hirsh, MD as Medical Director, Cardiology","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Hirsh, a cardiac electrophysiologist, joins Glucotrack's clinical advisory team for its CBGM program.","He will oversee clinical and educational initiatives supporting the CBGM's intravascular placement approach.","Glucotrack is advancing its CBGM through a long-term OUS early feasibility study and upcoming US pilot study.","CBGM is a long-term implantable system measuring glucose directly from blood, with up to 3-year sensor life."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137666,"accession_number":"0001493152-25-011509","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack to exhibit CBGM at ADCES; touts progress toward US pilot study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Presenting at ADCES Annual Meeting Aug 8-11, 2025 in Phoenix, AZ; CBGM at Booth #1724.","Poster: 'Endocrinologists’ Perspectives on an Implantable CBGM' on Aug 9, 12:00-1:00 PM MST.","Preparing to begin long-term early feasibility study after successful initial clinical validation.","CBGM is fully implantable, lasts up to 3 years, measures blood glucose directly with no on-body wearable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137663,"accession_number":"0001493152-25-011423","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K/A","filed_at":"2025-07-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Glucotrack dismisses Grant Thornton Israel as auditor, engages CBIZ CPAs effective July 18, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissal effective July 18, 2025; Grant Thornton reports for past two years included going-concern explanatory paragraph but no adverse opinion.","No disagreements on accounting principles or practices; material weaknesses in internal controls previously disclosed.","Audit committee engaged CBIZ as successor independent registered public accounting firm for FY 2025.","Grant Thornton provided letter dated July 25, 2025, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137665,"accession_number":"0001493152-25-011386","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Glucotrack dismisses Grant Thornton, engages CBIZ as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved dismissal of Fahn Kanne & Co. Grant Thornton Israel and engagement of CBIZ CPAs P.C., effective July 18, 2025.","Grant Thornton's reports for FY2024 and FY2023 included a going-concern explanatory paragraph but were otherwise unqualified.","No disagreements with Grant Thornton on accounting principles or audit scope during FY2024, FY2023, or subsequent interim period.","Material weaknesses in internal control over financial reporting previously disclosed (IT controls, accounting personnel, segregation of duties) were discussed with Grant Thornton.","Company will file Grant Thornton's response letter by amendment within two business days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137664,"accession_number":"0001641172-25-018104","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack repurchases ~49,700 Series A warrants, cuts potential dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased over 90% of Series A Warrants on June 30, 2025 for cash on hand in a negotiated transaction.","Approximately 4,300 Series A Warrants remain outstanding; company expects to buy back most of those.","Series B Warrants had been previously extinguished in exchange for common stock as of March 31, 2025.","Buyback eliminates warrant liability accounting and reduces future share dilution overhang."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155043,"accession_number":"0001641172-25-016387","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack reports positive final first-in-human CBGM study results with MARD 7.7%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study met all endpoints; MARD 7.7% across 122 matched pairs, 99% data capture, no serious adverse events.","92% of readings in green zone of Diabetes Technology Society Error Grid, none in unsafe zones.","Ten participants with Type 1 or Type 2 diabetes; device implanted via subclavian vein, monitored 4 days.","Glucotrack expects to initiate long-term early feasibility study in Q3 2025.","OneTwo Analytics applied AI/ML analytics to validate performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155042,"accession_number":"0001641172-25-015194","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Glucotrack executes 1-for-60 reverse stock split effective June 13, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split approved by stockholders on May 22; reduces outstanding shares from 34,047,337 to ~567,456.","No fractional shares issued; rounding up to next whole share for odd lots.","Ticker remains GCTK; split-adjusted trading begins June 16, 2025; new CUSIP 45824Q804.","Historical per-share net loss recast: FY2024 post-split basic loss $4,101.94 vs pre-split $68.44.","Q1 2025 post-split basic loss $40.14 vs pre-split $0.67; share count adjusted accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155041,"accession_number":"0001641172-25-014803","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack announces 1-for-60 reverse stock split effective June 16, 2025 to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-60 reverse stock split approved by shareholders on May 22, 2025, effective at market open on June 16, 2025.","Outstanding shares reduced from ~32.5M to ~542,356; no fractional shares issued, rounding up to next whole share.","Reverse split intended to bring GCTK into compliance with Nasdaq $1.00 minimum bid price requirement.","Company warns it may be delisted if it becomes deficient on any Nasdaq rule before September 29, 2025.","CUSIP changes to 45824Q804; trading symbol remains GCTK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155040,"accession_number":"0001641172-25-013543","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack to present first-in-human CBGM data at ADA 85th Scientific Sessions","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Will present safety & performance data from first-in-human trial of implantable continuous blood glucose monitor (CBGM).","Live presentation by CSO Mark Tapsak on June 21 in Innovation Hub; poster session June 22.","CBGM measures glucose directly from blood, lasts up to 3 years, no on-body wearable.","Company preparing for next clinical phase (long-term feasibility study)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155039,"accession_number":"0001641172-25-012287","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Glucotrack shareholders approve reverse stock split (up to 1:100) and increase equity plan shares to 7.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with ~59% of votes cast in favor; broker non-votes amounted to ~5.45M on each nominee.","Reverse stock split authorized at a ratio not exceeding 1:100; management will determine exact ratio.","Equity incentive plan share pool increased to 7.5 million shares from prior limit.","Auditor Fahn Kanne & Co. Grant Thornton Israel ratified with ~91% of votes cast in favor.","Quorum of 44.32% achieved with 11,339,896 shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155038,"accession_number":"0001641172-25-011610","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack forms Patient Advisory Board to guide implantable CBGM development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient Advisory Board (PAB) formed with leading diabetes patient advocates and voices.","Inaugural PAB meeting held on May 3, 2025; will convene regularly.","PAB aims to keep patient insights at the forefront of long-term implantable CBGM development.","CBGM is designed for up to 3 years of continuous blood glucose monitoring, no wearable component.","CBGM is an Investigational Device limited by federal law to investigational use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155037,"accession_number":"0001641172-25-010377","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glucotrack Q1 net loss widens to $6.8M; cash $9.1M; on track for CBGM study Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.8M vs $2.9M YoY; includes $3.4M non-cash derivative liability change.","R&D expense $1.9M (down $0.2M); MG&A $1.6M (up $0.8M on legal/professional fees).","Cash $9.1M at Mar 31, 2025 vs $5.6M at Dec 31, 2024; $6.4M from financing.","First patients in Australian CBGM feasibility study expected Q3 2025; FDA IDE pilot study expected Q4 2025.","First-in-human study met primary endpoint; no device-related serious adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155036,"accession_number":"0001641172-25-009849","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack receives ethics approval for 1-year CBGM clinical study in diabetes patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ethical approval from St. Vincent's Hospital Melbourne HREC for long-term CBGM study in type 1/2 diabetes.","Study plans up to 30 participants; initial 1-year evaluation, possible extension to 3 years.","First patient implants expected by July 2025; Principal Investigators Prof. David O'Neal and Assoc. Prof. Neale Cohen.","CBGM is implantable, measures blood glucose directly (vs interstitial fluid), no wearable component."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155035,"accession_number":"0001641172-25-006651","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack issued investor presentation on April 29, 2025; no details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1; content not disclosed in filing.","No financial figures, forecasts, or material updates included.","Filing under Regulation FD; information not deemed filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155034,"accession_number":"0001641172-25-004977","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack joins EU-funded FORGETDIABETES bionic pancreas initiative","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Glucotrack's CBGM will provide real-time glucose data for automated insulin delivery system.","FORGETDIABETES is funded by EU Horizon 2020 (€75B program) to develop a long-term bionic pancreas.","Partnership with University of Padova and other European research institutions.","Glucotrack CBGM is long-term implantable (3-year sensor), no on-body wearable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155033,"accession_number":"0001641172-25-002802","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Glucotrack receives Nasdaq delisting notice for bid price non-compliance; plans to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Glucotrack on April 2, 2025 of delisting due to bid price below $1.00 for 30 consecutive business days.","Company intends to request a hearing by April 9, 2025, which will stay the suspension pending Panel decision.","Compliance with Bid Price Rule was previously regained in November 2024; now again non-compliant.","No immediate impact on trading under symbol GCTK; outcome of appeal uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155032,"accession_number":"0001641172-25-002525","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack partners with OneTwo Analytics for AI-driven clinical data analysis of implantable CBGM","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Glucotrack (GCTK) enters collaboration with OneTwo Analytics AB to apply AI/ML analytics on its CBGM clinical study data.","CBGM is a long-term implantable device that measures glucose directly from blood, no external component, 3-year sensor life.","OneTwo Analytics specializes in diabetes data analytics; collaboration aims to quantify long-term benefits of CBGM.","No financial terms disclosed; agreement focuses on data analysis for clinical evaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173562,"accession_number":"0001641172-25-001831","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glucotrack FY2024 net loss $22.6M; completes first human CBGM study, expects IDE in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.6M vs $7.1M in 2023; R&D expense $9.5M (+$4.8M YoY) on increased product development activities.","Cash $5.6M at Dec 31, 2024; pro forma $11.9M after Q1 2025 offerings; raised $16.3M since Nov 2024.","First human clinical study of CBGM met primary endpoint with no device-related serious adverse events.","Appointed new CFO, VP Regulatory, VP Clinical Ops; expanded Medical Advisory Board.","Anticipates IDE approval from FDA in Q4 2025; long-term study in Australia expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173561,"accession_number":"0001493152-25-010873","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack to present first-in-human CBGM trial data at ATTD 2025 conference in Amsterdam","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safety and performance data from first-in-human trial of implantable CBGM system to be presented at ATTD conference, March 19-22, 2025.","Device measures glucose directly from blood, not interstitial fluid, with no on-body wearables, designed for 3-year continuous monitoring.","Trial is an early feasibility study in adults with diabetes; results support advancement to chronic implant study.","CEO Paul Goode highlights potentially transformative advancement in diabetes management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173560,"accession_number":"0001493152-25-010189","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Glucotrack issues 2.75M shares after cashless warrant exchange","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchange of 2,835,905 Series B warrants on March 11, 2025 resulted in 2,749,817 new common shares.","Warrants held by director-affiliated investor and other holders; exercised cashless with no additional consideration.","Issuance exempt under Section 3(a)(9) of Securities Act; no commissions paid.","Follows prior conversion of $4.4M in July notes and July 2024 debt into shares and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173559,"accession_number":"0001493152-25-008275","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack appoints diabetes expert Dr. Guillermo Umpierrez to Medical Advisory Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Umpierrez, Professor of Medicine at Emory and past ADA president for Medicine & Science, joins effective immediately.","He will provide strategic guidance as Glucotrack advances its long-term implantable CBGM system through clinical development.","Glucotrack's CBGM has 3-year sensor life, no wearable component, and measures blood glucose directly to reduce lag time.","CEO Paul Goode cites Dr. Umpierrez's clinical and research expertise as valuable for upcoming human trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173558,"accession_number":"0001493152-25-006856","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack distributes shareholder update slide presentation; no specific details in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company issued a slide presentation on February 14, 2025 as a shareholder update.","No financial or operational figures, guidance, or material events are disclosed in the 8-K filing.","Exhibit 99.1 is furnished but its content is not included in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173557,"accession_number":"0001493152-25-004953","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Glucotrack prices ~$3.0M public offering of 2.6M shares at $1.15 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2,638,042 shares priced at $1.15 each; gross proceeds ~$3.03M before fees.","Offering expected to close Feb 5, 2025; net proceeds for working capital.","Dawson James Securities acts as sole placement agent; 8% cash fee.","Directors and officers enter 180-day lock-up agreements post-closing.","30-day restriction on further share issuance or variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173556,"accession_number":"0001493152-25-004793","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["5.03","7.01","8.01","9.01"],"status":"ready","headline":"Glucotrack completes 1:20 reverse stock split; first human CBGM study successful with no serious adverse events","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Feb 3, 2025, every 20 pre-split shares combined into 1 share; outstanding shares reduced from ~155.5M to ~7.8M.","First in-human CBGM study met primary endpoint: no procedure- or device-related serious adverse events from implant through 7 days post-removal.","Six participants with diabetes mellitus; CBGM sensor lead placed intravascularly in subclavian vein for 4-day in-hospital monitoring.","Study confirmed CBGM sensor lead function; system accuracy consistent with prior animal studies; next step is long-term clinical trials.","Ticker GCTK unchanged; new CUSIP 45824Q705; shares trade on split-adjusted basis from Feb 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173555,"accession_number":"0001493152-25-004216","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack announces 1-for-20 reverse stock split to regain Nasdaq compliance effective Feb 4, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-20 reverse split effective at market open on Feb 4, 2025; shares reduce from ~155.5M to ~7.77M.","No fractional shares issued; holders receive additional fraction to round up to whole share.","Board approved 1-for-20 ratio on Jan 28, 2025, following stockholder authorization on Jan 3, 2025.","Reverse split intended to meet Nasdaq $1.00 minimum bid price requirement and attract institutional investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173554,"accession_number":"0001493152-25-004104","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Glucotrack CFO James Cardwell resigns; Peter Wulff appointed as CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Cardwell resigned as CFO effective Jan 27, 2025; will remain as consultant for transition.","Peter Wulff appointed CFO effective Jan 28, 2025; has 40+ years life sciences finance experience.","Wulff's base salary: $300k for 2025, $450k thereafter; eligible for bonuses tied to financing milestones up to $262.5k total.","Initial equity grant of options for 1.25% of outstanding common stock under 2024 Equity Incentive Plan.","Wulff most recently CFO at Biological Dynamics; previously CFO at JenaValve Technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173553,"accession_number":"0001493152-25-002950","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack receives ISO 13485:2016 certification for quality management system","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Certification awarded by British Standards Institute after Stage I and Stage II assessments.","Covers design and development of Glucotrack's long-term implantable Continuous Blood Glucose Monitor (CBGM).","ISO 13485 is the globally recognized standard for medical device QMS, aligned with FDA QMSR and used in the EU.","CEO Paul Goode calls certification a major step toward delivering high-quality products.","No financial updates or guidance changes provided in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173549,"accession_number":"0001493152-25-002027","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K/A","filed_at":"2025-01-14T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Glucotrack corrects warrant exchange shares; 134.8M shares issued for 6.95M warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exchanged 6,950,240 Series B Warrants for 134,785,015 common shares from Jan 6-13, 2025.","Remaining 3,079,905 Series B Warrants are exchangeable for about 59,728,158 shares.","Amendment fixes a scrivener's error in the original 8-K regarding issuable shares on remaining warrants.","Warrants allowed cashless exercise for up to 300% of underlying shares; no additional consideration received."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173552,"accession_number":"0001493152-25-001982","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Glucotrack issues 134.8M shares upon cashless exchange of 6.95M Series B Warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exchanged 6,950,240 Series B Warrants for 134,785,015 shares of common stock.","Remaining 3,079,905 Series B Warrants are exchangeable for ~19,909,386 additional shares.","Exchange was cashless under Section 3(a)(9) exemption; no cash paid by holders.","Share count will increase by 134.8M shares, causing substantial dilution to existing stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-01-13T23:59:59+00:00|173552"}